Biomatter
Designs custom enzymes with computational models and laboratory testing for industrial and life-sciences customers.
Website: https://biomatter.ai/
Cover Block
Publicly reported
| Field | Detail |
|---|---|
| Company | Biomatter |
| Tagline | Designs custom enzymes with computational models and laboratory testing for industrial and life-sciences customers. [VU.lt, November 2026] |
| Headquarters | Vilnius, Lithuania [Crunchbase] |
| Founded | 2018 [Vestbee, November 2026] |
| Stage | Series A [VU.lt, November 2026] |
| Business model | B2B |
| Industry | Deeptech |
| Technology | AI / Machine Learning |
| Geography | Western Europe |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (3+) [Vestbee, November 2026] |
| Funding label | $10M+ |
| Total disclosed funding | ~$20,100,000, based on a $2,100,000 seed in May 2022 and an $18,000,000 Series A in November 2026 (estimated) [Forbes, May 2022] [VU.lt, November 2026] |
Links
Publicly reported
- Website: https://biomatter.ai/
- LinkedIn: https://lt.linkedin.com/company/biomatter
Summary and Signal
PUBLIC Biomatter designs and delivers custom enzymes for industrial and life-sciences customers, and it merits investor attention now because its November 2026 Series A financing arrived alongside a more commercially mature story than most computational-biology startups can show in public, including disclosed product deployments and reported repeat enterprise work [VU.lt, November 2026] [Vestbee, November 2026]. The company traces back to research begun in 2017 at Vilnius University’s Institute of Biotechnology, where Laurynas Karpus, Vykintas Jauniškis, and Irmantas Rokaitis started exploring AI-generated enzymes before establishing Biomatter in 2018 with Donatas Repečka and Rolandas Meškys [Move the Needle, November 2026] [Vestbee, November 2026].
The core offer is not software sold on its own, but a design-and-deliver service that combines computational models with laboratory testing to produce custom enzymes, including for reactions where no natural enzyme is known, which is a sharper commercial position than a pure discovery platform if execution holds [VU.lt, November 2026] [Vestbee, November 2026]. Public materials also point to early technical credibility: Biomatter says its work is incorporated into Thermo Fisher Scientific’s Invitrogen SuperScript V Reverse Transcriptase, and multiple sources tie the company to early research on functional enzymes created with generative AI and published in Nature Machine Intelligence [Businesswire] [TechFundingNews, November 2026] [LithuaniaBIO] [SynBioBeta].
On the team side, the public record supports a research-heavy founding bench anchored in enzyme engineering and the Vilnius University ecosystem, with Karpus serving as CEO and the founding group consistently identified across recent coverage and professional profiles [Move the Needle, November 2026] [LinkedIn] [Forbes, May 2022]. Capital formation is comparatively straightforward: Forbes reported a $2.1 million seed round led by Practica Capital in May 2022, and VU.lt reported an $18 million Series A led by Astanor in November 2026 with participation from UVC Partners, Inventure, and Metaplanet, bringing total disclosed funding to about $20.1 million [Forbes, May 2022] [VU.lt, November 2026].
The business model is B2B custom enzyme development, and the public traction claim is more substantial than usual for a company at this stage, with more than 50 custom enzymes delivered to more than 25 enterprise customers across Europe, the United States, and Japan, although those operating figures still rely heavily on company-linked reporting and should be treated with some caution [VU.lt, November 2026] [TechGrid Media] [mykxlg.com]. Over the next 12 to 18 months, the key question is whether Biomatter can convert its scientific positioning into a repeatable commercial engine, especially as it expands its U.S. presence, builds out design-and-testing capacity in Vilnius, and seeks to turn named relationships such as Neogen and Thermo Fisher-linked work into evidence of durable, scaled demand [Move the Needle, November 2026] [Neogen Corporation, August 2025] [TechFundingNews, November 2026].
One source, partially checked -- Core funding and founding history are corroborated by multiple public sources, but several traction and product-deployment claims remain partly dependent on company-linked or announcement-based reporting.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series A |
| Business Model | B2B |
| Industry / Vertical | Deeptech |
| Technology Type | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | $10M+ total disclosed, approximately $20.1M [Forbes, May 2022] [VU.lt, November 2026] |
Company Overview
PUBLIC
Biomatter is a Vilnius, Lithuania-based biotechnology company founded in 2018, focused on designing custom enzymes for industrial and life-sciences customers [Crunchbase]. Public company materials describe the business as combining computational enzyme design with laboratory testing and delivering the resulting enzymes as a commercial product, rather than selling software alone [biomatter.ai, January 2026].
The founding record is reasonably consistent across public databases and company materials, even if the fuller founder roster is better documented outside the narrow source set used here. Crunchbase lists Biomatter as founded in 2018 and headquartered in Vilnius, while the company website presents Biomatter as a protein engineering company built around AI-driven enzyme design and lab validation workflows [Crunchbase] [biomatter.ai, January 2026].
The clearest public milestones are clustered around financing and commercialization. Crunchbase records disclosed funding activity for Biomatter, and the company website shows an active corporate presence with dedicated news and careers pages as of 2026, which supports the view that the company has moved beyond a research-stage academic origin into an operating commercial entity [Crunchbase] [biomatter.ai, January 2026]. The public source base used for this section does not establish the legal entity name with filing-level precision, so that point is best treated as open pending direct corporate documentation [Crunchbase] [biomatter.ai, January 2026].
One source, partially checked -- Based on Crunchbase and company website materials; headquarters, founding year, and business description are corroborated, but legal entity detail is not established from the cited source set.
The Product and the Stack
MIXED
The product story is unusually concrete for a young enzyme-design company. Biomatter says it designs custom enzymes with computational models and laboratory testing, then delivers those enzymes to industrial and life-sciences customers rather than stopping at software outputs alone [VU.lt, November 2026] [Vestbee, November 2026]. That matters because the commercial offer is framed as an order-and-deliver service, not a research tool license: Vilnius University coverage describes the company’s aim as making a custom enzyme as easy to order as a catalog product, including enzymes for reactions where no natural counterpart exists [VU.lt, November 2026].
The underlying technical claims are ambitious but at least directionally consistent across sources. Biomatter and third-party coverage describe an AI and physics-based design stack for novel enzymes and enzyme optimization, with the company’s LYNX product positioned around improving activity, stability, and yield from a sequence input [Vestbee, November 2026] [Apex Bio Consulting]. Company materials also tie the platform back to earlier generative-enzyme research, stating that Biomatter unveiled fully functional enzymes created with generative AI in work published in Nature Machine Intelligence, while outside coverage repeats that claim with similar framing [biomatter.ai, January 2026] [LithuaniaBIO] [SynBioBeta]. The evidence base here is still weighted toward company-linked or announcement coverage, so the technical differentiation should be read as credible but not yet independently benchmarked in public.
There is at least some public evidence that the technology has crossed from design into deployed use. BusinessWire-linked coverage and trade press report that Biomatter’s work is incorporated into Thermo Fisher Scientific’s Invitrogen SuperScript V Reverse Transcriptase, with TechFundingNews and Pharma Journalist describing the contribution as improving oxidation resistance for an enzyme used in RNA-to-DNA conversion and mRNA-related workflows [Businesswire] [TechFundingNews, November 2026] [Pharma Journalist]. Separately, Neogen said in August 2025 that it had entered into an arrangement with Biomatter to use the company’s enzyme design capabilities, and subsequent coverage described that work as focused on enzyme-based food safety products [Neogen Corporation, August 2025] [Investing.com]. Those references do not establish the full performance delta versus incumbent enzyme engineering methods, but they do suggest the platform is being judged on commercial outputs rather than research novelty alone.
One source, partially checked -- Product description is corroborated across VU.lt and Vestbee, but several deeper technical and deployment claims rely on company-linked or trade-press reporting.
The Market They Are Entering
PUBLIC
The market matters now because enzyme design sits at the intersection of two active spending pools, industrial biotechnology and life-sciences R&D, and Biomatter is trying to sell into both with a delivered-product model rather than pure software [VU.lt, November 2026] [Vestbee, November 2026].
Public evidence on Biomatter's exact addressable market is thin, so the cleaner approach is to frame the opportunity through adjacent markets rather than force a false precision. The company is described as selling custom enzymes to buyers in biopharma, diagnostics, agriculture, food, and industrial biotechnology [VU.lt, November 2026]. That points to a broad serviceable market defined less by one budget line and more by a recurring technical need: companies that need enzymes with higher stability, altered specificity, or performance under non-natural reaction conditions [Vestbee, November 2026] [VU.lt, November 2026].
The demand signal in the public record is commercial, not just scientific. Biomatter said in November 2026 that it had delivered more than 50 custom enzymes to more than 25 enterprise customers across Europe, the United States, and Japan [VU.lt, November 2026]. Trade coverage also ties its work to named downstream applications, including Thermo Fisher Scientific's Invitrogen SuperScript V Reverse Transcriptase and an August 2025 relationship with Neogen on enzyme-based products, which suggests buyers are evaluating enzymes as product components rather than research curiosities [TechFundingNews, November 2026] [Neogen Corporation, August 2025].
The nearest substitute markets are contract research, incumbent catalog enzymes, and internal R&D teams inside large pharma, diagnostics, and industrial biotech groups. Biomatter's stated wedge is that a custom enzyme should be as easy to order as a catalog product, including for reactions where no natural enzyme exists, which implies it is competing against slow bespoke discovery workflows and against off-the-shelf enzymes that are good enough but not optimized for a customer's process [VU.lt, November 2026]. If that claim holds in practice, the company is participating in a shift from enzyme sourcing as procurement to enzyme design as a performance input.
Regulatory and macro forces likely help, even if the sources stop short of quantifying them. Buyers in food safety, molecular biology, biopharma, and industrial processing face persistent pressure to improve yield, specificity, and manufacturing efficiency, and enzymes can be a route to all three when they work inside validated workflows [Investing.com] [TechFundingNews, November 2026]. At the same time, the adoption burden is real: in regulated settings, a better enzyme still needs to fit established assay, manufacturing, or quality systems, which tends to lengthen sales cycles and raises the value of evidence from deployed products such as Thermo Fisher's reverse transcriptase line [Businesswire] [TechFundingNews, November 2026].
Because no named third-party market sizing report was captured in the source set, the most reliable market view here is qualitative and adjacency-based rather than a TAM figure dressed up as certainty.
| Market lens | What the sources support | Why it matters to Biomatter |
|---|---|---|
| Core buying need | Custom enzymes for specific reactions and industrial applications [Vestbee, November 2026] | Supports a premium, problem-specific value proposition rather than a generic software sale |
| End markets mentioned | Biopharma, diagnostics, agriculture, food, industrial biotechnology [VU.lt, November 2026] | Suggests diversified demand exposure across research and production use cases |
| Geographic demand signal | Customers across Europe, the United States, and Japan [VU.lt, November 2026] | Indicates the opportunity is not limited to the Lithuanian biotech ecosystem |
| Substitute solutions | Catalog enzymes, internal R&D, and bespoke discovery workflows (analyst inference from company positioning) [VU.lt, November 2026] [Vestbee, November 2026] | Clarifies that Biomatter must win on speed, fit, and downstream performance |
The table points to a market that is broad in application but still narrow in proof points. The commercial case rests less on top-down sizing and more on whether custom-designed enzymes can move from pilot projects into repeat purchasing across regulated customer environments.
One source, partially checked -- Section relies on one primary public company-linked announcement, one trade report, and a limited set of corroborating public articles; no independent third-party TAM report was captured in the source set.
The Competitive Field
Competitive map
MIXED Biomatter appears to be competing less against a single named startup peer in the public record than against a stack of alternatives: in-house enzyme engineering teams at large life-sciences and industrial companies, catalog reagent vendors, and software-first protein design groups that stop short of delivering a finished wet-lab result [VU.lt, November 2026] [Vestbee, November 2026].
That positioning matters because the company's public case rests on a service model, not just a model-building claim. Biomatter says it combines computational design with laboratory testing and delivers custom enzymes to industrial and life-sciences customers, with the stated aim of making a custom enzyme as easy to order as a catalog product [Vestbee, November 2026] [VU.lt, November 2026]. In practice, the nearest substitutes for a buyer may therefore be an internal R&D program, an existing supplier such as Thermo Fisher for off-the-shelf reagents, or a contract research relationship, rather than a clearly disclosed venture-backed startup rival [Businesswire] [VU.lt, November 2026].
The incumbent set is easiest to see in customer references. Thermo Fisher Scientific is not framed publicly as a direct competitor, but it represents a powerful adjacent substitute because it already owns broad laboratory distribution and Biomatter's work is reported to be incorporated into Thermo Fisher's Invitrogen SuperScript V Reverse Transcriptase [Businesswire] [TechFundingNews, November 2026]. Neogen sits in a similar adjacent category on food safety, where the August 2025 relationship suggests Biomatter can plug into a larger commercial and product channel rather than having to build one alone [Neogen Corporation, August 2025] [biomatter.ai, August 2025].
The challenger set is more implied than named. Public coverage describes Biomatter as an AI-powered enzyme design company and points back to its Nature Machine Intelligence work on generative enzyme design, which places it in the broader protein-design cohort even if the supplied source set does not name specific peers [VU.lt, November 2026] [SynBioBeta]. That absence is itself informative: Biomatter is being covered publicly through commercial outcomes, customers, and delivered enzymes, while many companies in the broader computational biology field are still discussed mainly through platform potential.
Edge and exposure
MIXED The clearest edge visible today is product scope. Biomatter is not presented as a software vendor selling design tools into customer labs; it is presented as a company that designs, tests, and delivers finished enzymes, including for reactions with no natural counterpart [Vestbee, November 2026] [VU.lt, November 2026]. If that claim holds in practice, the advantage is a shorter path from computational insight to customer deployment, and potentially a tighter feedback loop from wet-lab outcomes back into model improvement [biomatter.ai, January 2026] [Apex Bio Consulting].
That edge is credible but somewhat perishable. It is helped by the company's academic origin at Vilnius University's Institute of Biotechnology and by early evidence that its designed enzymes have made their way into a Thermo Fisher product and into relationships with enterprise buyers such as Neogen [Move the Needle, November 2026] [Businesswire] [Neogen Corporation, August 2025]. Still, large reagent suppliers and biopharma companies can bring deeper balance sheets, installed commercial relationships, and regulatory experience once a category proves valuable, which means Biomatter's advantage likely depends on speed, proprietary design data, and customer-specific execution rather than on capital alone [TechFundingNews, November 2026] [VU.lt, November 2026].
The exposure is straightforward. Thermo Fisher, while also a commercialization proof point, illustrates how much power sits with incumbents that control distribution, product packaging, and end-customer trust in research workflows [Businesswire]. If buyers prefer validated components embedded in existing supplier catalogs, Biomatter could remain an upstream design partner rather than the enduring owner of the customer relationship, especially in categories where procurement and regulatory validation reward scale and historical reliability [TechFundingNews, November 2026] [Pharma Journalist].
Most plausible 18-month scenario
MIXED The most plausible near-term outcome is not winner-take-all, but selective channel capture. Biomatter has the ingredients for share gains in custom projects where a buyer needs a novel enzyme quickly and cannot justify building the capability internally, particularly across biopharma, diagnostics, food, and industrial biotechnology where the company says it already operates [VU.lt, November 2026]. In that scenario, the winner if custom design demand keeps moving toward outsourced, order-and-deliver workflows is Biomatter itself, because its public differentiation is built around delivering the enzyme rather than merely proposing a sequence [Vestbee, November 2026] [BioXconomy, November 2026].
The loser if that shift stalls is the software-only end of the category, broadly defined, because buyers in regulated or production settings usually care about validated performance more than model elegance. There is a second scenario, though, where Thermo Fisher is the practical winner if enterprise demand consolidates around incumbent channels and customers prefer to buy improved enzymes inside familiar product families rather than through a newer standalone vendor [Businesswire] [TechFundingNews, November 2026]. On the current public evidence, Biomatter looks competitively strongest as an enabling layer inside high-value workflows, and less proven as the long-term owner of the full commercial channel.
One source, partially checked -- This section relies on corroborated public reporting for Biomatter's product model, funding context, and commercial relationships, but the source set names no direct startup competitors and several commercial claims remain company-led or trade-press repeated [VU.lt, November 2026] [Vestbee, November 2026] [Businesswire].
Opportunity
Upside case
PUBLIC The prize here is not another enzyme services firm, but a company that could become the operating layer for custom biocatalyst design in sectors where a better enzyme changes product performance, manufacturing yield, or time-to-market [VU.lt, November 2026] [Vestbee, November 2026].
The headline opportunity is straightforward. If Biomatter can make custom enzyme design feel as purchasable and repeatable as buying from a catalog, it has a route to becoming the default external partner for industrial and life-sciences teams that need a molecule nature did not already provide [VU.lt, November 2026]. That outcome is reachable, not merely aspirational, because the public record shows three ingredients already in place: the company sells delivered enzymes rather than software alone [Vestbee, November 2026]; it says it has shipped more than 50 custom enzymes to more than 25 enterprise customers across Europe, the United States, and Japan [TechGrid Media] [mykxlg.com]; and its work has been tied to a commercial Thermo Fisher product, Invitrogen SuperScript V Reverse Transcriptase, in trade and company-adjacent coverage [TechFundingNews, November 2026] [Businesswire]. Taken together, that suggests Biomatter is trying to own a workflow that customers will pay for at the product level, not just at the tooling level.
The more interesting point is where the business could sit in the value chain if execution holds. Enzyme design is relevant across biopharma, diagnostics, agriculture, food, and industrial biotechnology, according to company-backed reporting on the Series A [VU.lt, November 2026]. A platform that can repeatedly shorten search time for useful enzymes, including reactions with no natural counterpart, could move from bespoke project work into a position closer to strategic infrastructure for R&D and product teams [VU.lt, November 2026] [Vestbee, November 2026]. That would matter because infrastructure vendors tend to compound faster than pure services shops when they become embedded in customer development pipelines.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Embedded biocatalyst supplier | Biomatter becomes the recurring external design partner for large pharma, diagnostics, and industrial biotech programs, with customers returning for successive enzyme programs rather than one-off projects | The company already claims more than 25 enterprise customers and more than 50 delivered enzymes, which implies repeatable commercial delivery if customer satisfaction is holding [mykxlg.com] [TechGrid Media] | Biomatter combines computational design with lab testing and delivers finished enzymes, which fits how enterprise buyers purchase outcomes rather than tooling alone [Vestbee, November 2026] |
| Commercial proof through flagship products | A small number of enzymes designed or optimized by Biomatter make their way into widely used end products, turning technical credibility into a stronger sales motion | Public linkage to Thermo Fisher's Invitrogen SuperScript V Reverse Transcriptase and the Neogen relationship provide visible reference points [TechFundingNews, November 2026] [Neogen Corporation, August 2025] | Enterprise biotech buyers often underwrite platform risk only after seeing product-grade validation. Biomatter already has public examples that can serve as that validation, even if the revenue impact is not disclosed [Businesswire] [TechFundingNews, November 2026] |
| Design platform with geographic expansion | The company uses new capital to build a deeper commercial presence in the US while expanding design-and-testing capacity in Vilnius, broadening both deal flow and throughput | The Series A was announced at $18 million, led by Astanor, and reporting tied the financing to commercial expansion and a Vilnius design-and-testing facility [VU.lt, November 2026] [Move the Needle, November 2026] | This is plausible because Biomatter has already sold across Europe, the US, and Japan, so the next leg is more likely density in existing corridors than speculative greenfield expansion [VU.lt, November 2026] [TechGrid Media] |
The compounding mechanism is visible even in the limited public record. Every delivered enzyme can improve the company's understanding of which computational approaches survive laboratory testing and matter in specific industrial contexts, while every enterprise reference account lowers the burden of proof for the next one [Vestbee, November 2026] [VU.lt, November 2026]. If Biomatter's LYNX and broader AI and physics-based design stack are actually reducing optimization time, then one customer win does more than add revenue, it also adds training signal, application knowledge, and a stronger case for adjacent use cases in the same account or vertical [biomatter.ai, January 2026] [Apex Bio Consulting].
That flywheel could become meaningful because the company is not positioned only as a software provider. By combining computational design with laboratory validation and delivering the enzyme itself, Biomatter can sit closer to the customer's end product and capture the value of performance rather than charging only for access to a model [Vestbee, November 2026]. The Neogen arrangement also hints at a second layer of compounding, where a design capability paired with an incumbent's distribution and domain expertise can open category-specific channels faster than direct selling alone [Neogen Corporation, August 2025].
The size of the win is best framed as a scenario, not a forecast. There is no confirmed public market-sizing figure in the source set, and no disclosed revenue base from which to model outcomes. Still, if Biomatter becomes a trusted upstream design-and-delivery platform for enzymes used by large life-sciences and industrial customers, the valuation frame starts to resemble a strategic infrastructure asset rather than a contract research business, especially given that investors such as Astanor, UVC Partners, Inventure, and Practica Capital have backed the company through a disclosed roughly $20.1 million in funding [VU.lt, November 2026] [Forbes, May 2022]. In that scenario, not a forecast, the company could plausibly support venture-scale value creation through either strategic acquisition by a life-sciences tools player or by becoming a scaled independent platform with multiple enterprise verticals. Public evidence is not yet strong enough to put a clean number on that upside without importing outside comparables not present in this record.
One source, partially checked -- Section relies on one independent funding source and several trade or company-adjacent reports for customer, product, and deployment claims, with no confirmed public revenue or market-size benchmark in the source set.
Sources
Publicly reported
[VU.lt, November 2026] Vilnius University-born startup Biomatter raises 18 million in investment 1 | https://www.vu.lt/en/all-news/vilnius-university-born-startup-biomatter-raises-18-million-in-investment-1
[Crunchbase] Biomatter - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/biomatter-designs
[Vestbee, November 2026] Biomatter raises $18M Series A to accelerate AI-powered enzyme design | https://www.vestbee.com/insights/articles/biomatter-raises-18-m
[Forbes, May 2022] Biomatter Designs | https://www.forbes.com/profile/biomatter-designs
[Move the Needle, November 2026] Biomatter raises $18 million to speed up AI enzyme design | https://www.movetheneedle.news/start-ups/biomatter-raises--18-million-to-speed-up-ai-enzyme-design/
[Businesswire] Newsroom | https://www.businesswire.com/newsroom?industry=1778606
[TechFundingNews, November 2026] Biomatter lands $18M from Astanor and UVC Partners to build a Vilnius enzyme lab | https://techfundingnews.com/biomatter-lands-18m-from-astanor-and-uvc-partners-to-build-a-vilnius-enzyme-lab/
[biomatter.ai, January 2026] Biomatter | Protein Architects | https://biomatter.ai/
[Neogen Corporation, August 2025] Biomatter Establishes Relationship with Neogen | https://biomatter.ai/resources/news/biomatter-establishes-relationship-with-neogen/
[BioXconomy, November 2026] Biomatter banks $18m to turn enzyme design into an order-and-deliver business | https://www.bioxconomy.com/investment/biomatter-banks-18m-to-turn-enzyme-design-into-an-order-and-deliver-business
[biomatter.ai, August 2025] Biomatter Establishes Relationship with Neogen | https://biomatter.ai/resources/news/biomatter-establishes-relationship-with-neogen/
[LinkedIn] Biomatter | LinkedIn | https://lt.linkedin.com/company/biomatter
Articles about Biomatter
- Biomatter Is Delivering a Custom Enzyme Like a Catalog Product — The Lithuanian startup’s bet is that full-stack design and delivery can turn bespoke protein engineering into an order-and-deliver business.